Home › Search
Search
314 results for "lecanemab".
Research summaries 285
Showing the best 200 of 285, 101–110, page 11 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-donanemab-38253184
… efficacy of donanemab and lecanemab was significantly higher than placebo. Compared to placebo, donanemab and lecanemab were significantly less acceptable and tolerable. Aducanumab was also less well tolerated compared to …
-
Research summaries · alzhub.org/study/lecanemab-adoption-and-geographic-variation-among-patients-with-41433980
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. Women consisted of 53.1% the infusion …
-
Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in CanadaResearch summary
Research summaries · alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). In contrast, Aducanumab …
-
Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemabResearch summary
Research summaries · alzhub.org/study/balancing-benefit-and-risk-in-early-alzheimer-s-disease-the-european-41852829
… regulatory approvals of lecanemab and donanemab in the EU mark a significant milestone. Both antibodies, developed within the amyloid hypothesis, demonstrated statistically significant effects on cognitive and functional outcomes …
-
Research summaries · alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-aducanumab-40386876
… effective than aducanumab, lecanemab, and donanemab. Furthermore, rTMS was not significantly inferior to placebo/sham stimulation in tolerability and acceptability, whereas aducanumab, lecanemab, and donanemab were significantly …
-
Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in ChinaResearch summary
Research summaries · alzhub.org/study/determinants-of-treatment-willingness-and-willingness-to-pay-for-40955711
… real-world adoption of lecanemab than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay, informing patient-centred clinical decision pathways. W treat showed a strong direct …
-
Research summaries · alzhub.org/study/lecanemab-in-patients-with-early-alzheimer-s-disease-detailed-results-36544184
Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The …
-
Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysisResearch summary
Research summaries · alzhub.org/study/real-world-application-of-lecanemab-in-early-stage-alzheimer-s-41250246
… Following 12 months of lecanemab therapy, amyloid PET exhibited a significant reduction in brain amyloid burden. These data support that lecanemab appears to be generally tolerated in Asian population. The IRSE and ARIA-E events …
-
Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer’s disease: Evidence from a multidimensional real-world studyResearch summary
Research summaries · alzhub.org/study/safety-and-effectiveness-of-lecanemab-in-chinese-patients-with-early-41069006
… compared to baseline. Lecanemab demonstrated a favorable safety profile in Chinese patients with early AD. Cognitive stability and biomarker changes over 6 months suggest potential efficacy, though high dropout rates and absence …
-
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpointResearch summary
Research summaries · alzhub.org/study/the-affordability-of-lecanemab-an-amyloid-targeting-therapy-for-37251789
Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.